Clinical Trial Update: Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy [Phase 2]

View source ↗

Summary

This update announces a Phase IIa clinical trial evaluating anti-CD19 CAR T-cell therapy for systemic sclerosis resistant to immunosuppression. The study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• Anti-CD19 CAR-T cell therapy (CD19-targeted chimeric antigen receptor T cells)

Snippet

Sponsor: University Hospital, Montpellier | Conditions: Scleroderma, Systemic | Phase 2 | Status: NOT_YET_RECRUITING